Sant Pau - Institut de Recerca

Main lines of research

Study of the molecular and cellular pathophysiology of haematological cancers.
Study of the prognostic value of clinical and biological parameters in haematological malignancies.
Design of new modalities of chemotherapy, biotherapy and drug treatment targeting molecular mechanisms.
Design of new modalities of haematopoietic stem-cell transplantation and cell therapy.
Psychological intervention and quality of life in patients with haematological malignancies.

Challenges

Identify new prognostic parameters for risk and therapeutic stratification.
Evaluate targeted therapy in cell lines and animal models (with the Oncogenesis and Antitumour Drugs group).
Reduce toxicity and increase availability of allogeneic transplants.
Molecularly characterize acute myeloid leukaemia and determine the prognostic value of known genes and other genes of uncertain significance (with the Haematology Laboratory).
Model leukaemia and lymphoma in animals to better understand cell physiopathology and test new drugs (with the Oncogenesis and Antitumour Drugs group).
Molecularly characterize and determine the prognostic significance of cell physiopathology and immunotherapy for lymphoproliferative diseases and evaluate antitumour immunotherapy in animals and humans.

Group coordination

BRIONES MEIJIDE, JAVIER FGS
jbriones@santpau.cat

Members

Arguello de Tomas, Miquel IR
Bober, Anna IR
Caballero Gonzalez, Ana Carolina FGS
Castellet Farrus, Helena IR
De La Riva Buissen, Antonio IR
De Rueda Gamboa, Maria Jessica IR
Escriba Garcia, Laura IR
Esquirol Sanfeliu, Albert FGS
Garcia Cadenas, Irene FGS
Gonzalez Alvarez, Iria FGS
Grau Novellas, Neus IR
Guardiola Perello, Maria IR
Iranzo Ribera, Eva IR
Lopez Moreno, Sonia IR
Lopez Pardo, Jordi FGS
Martino Bofarull, Rodrigo FGS
Miqueleiz Alamos, Sara IR
Montserrat Torres, Rosanna IR
Perez Garcia, Nuria IR
Pujol Fernandez, Paula IR
Rodriguez Fernandez, Diana IR
Rosal Muntadas-Prim, Maria Josefa IR
Saavedra Gerosa, Silvana Daniela FGS
Sierra Gil, Jordi FGS
Ujaldon Miro, Cristina IR

Publications 2022

(JIF 2022)

Albiol N, Barata A, Aso O, Gomez L, Triquell M, Roch N, Lazaro E, Esquirol A, Gonzalez I, Lopez J, Sierra J, Martino R, Garcia I. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. SUPPORTIVE CARE IN CANCER. 2022; 30(12). DOI:10.1007/s00520-022-07376-w. PMID:36169731. IF:3,1 (Q1/3D). Document type: Article.
Allan JN, Shanafelt T, Wiestner A, Moreno C, O’Brien SM, Li JL, Krigsfeld G, Dean JP, Ahn IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(4). DOI:10.1111/bjh.17984. PMID:34865212. IF:6,5 (Q1/3D). Document type: Article.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso CE, Cortes JE, Dal P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gokbuget N, Gotlib J, Hellstrom E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le MM, Loh MLC, et al. [Sierra J]. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. BLOOD. 2022; 140(11). DOI:10.1182/blood.2022015850. PMID:35767897. IF:20,3 (Q1/1D). Document type: Article.
Arguello M, Albiol N, Jara P, Sierra J, Mora A, Moreno C. CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center. Clinical Lymphoma Myeloma & Leukemia. 2022; 22. DOI:10.1016/S2152-2650(22)01349-0. PMID:36163896. IF:2,7 (Q3/7D). Document type: Article.
Arranz MJ, Salazar J, Bote V, Artigas A, Serra A, Trivino E, Roige J, Lombardia C, Cancino M, Hernandez M, Cendros M, Duran E, Maraver N, Hervas A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. 2022; 14(5):999. DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5,4 (Q1/2D). Document type: Article.
Baptista MJ, Tapia G, Munoz AM, Muncunill J, Garcia O, Montoto S, Gribben JG, Calaminici M, Martinez A, Veloza L, Martinez A, Aldamiz T, Menarguez J, Terol MJ, Ferrandez A, Alcoceba M, Briones J, Gonzalez E, Climent F, Muntanola A, Moraleda JM, Provencio M, Abrisqueta P, Abella E, Colomo L, Garcia C, Garcia M, Sancho JM, Ribera JM, Mate JL, Navarro JT. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. HISTOPATHOLOGY. 2022; 81(6). DOI:10.1111/his.14798. PMID:36109172. IF:6,4 (Q1/2D). Document type: Article.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li J-Y, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11). DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7,5 (Q1/2D). Document type: Article.
Bataller A, Garrido A, Guijarro F, Onate G, Diaz M, Arnan M, Tormo M, Vives S, de Llano MPQ, Coll R, Gallardo D, Vall F, Escoda L, Garcia A, Salamero O, Sampol A, Merchan BM, Bargay J, Castano S, Esteban D, Oliver A, Rivero A, Mozas P, Lopez M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances. 2022; 6(4). DOI:10.1182/bloodadvances.2021005585. PMID:34911079. IF:7,5 (Q1/2D). Document type: Article.
Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko J, Tanase A, Akhtar S, Ben T, Ma’koseh M, Afanasyev B, Cheikh J, Briones J, Gulbas Z, Hamladji RM, Elverdi T, Blaise D, Martinez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. LEUKEMIA. 2022; 36(6). DOI:10.1038/s41375-022-01563-8. PMID:35414657. IF:11,4 (Q1/1D). Document type: Article.
Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu EM, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA. 2022; 63(6). DOI:10.1080/10428194.2021.2020779. PMID:35014928. IF:2,6 (Q3/7D). Document type: Article.
Caballero AC, Escriba L, Alvarez C, Briones J. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology. 2022; 13:904497. DOI:10.3389/fimmu.2022.904497. PMID:35874685. IF:7,3 (Q1/3D). Document type: Review.
Corrochano M, Acosta R, Mojal S, Miqueleiz S, Rodriguez D, Quijada MA, Fraga E, Castillo M, Amaro K, Albiol N, Soria JM, Antonijoan RM, Souto JC. Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2022; 53(1). DOI:10.1007/s11239-021-02507-2. PMID:34138399. IF:4 (Q2/4D). Document type: Article.
Diaz J, Rodriguez R, Coll R, Osca G, Pratcorona M, Gonzalez M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Diez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall F, Esteve J, Sierra J, Gallardo D, Cooperativo Estudio Tratamient GRP. 5 ‘-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. EUROPEAN JOURNAL OF HAEMATOLOGY. 2022; 109(6). DOI:10.1111/ejh.13862. PMID:36063368. IF:3,1 (Q3/6D). Document type: Article.
Dlouhy I, Karube K, Enjuanes A, Salaverria I, Nadeu F, Ramis JE, Valero JG, Rivas A, Magnano L, Martin D, Perez P, Clot G, Rovira J, Jares P, Balague O, Gine E, Mozas P, Briones J, Sancho JM, Salar A, Mercadal S, Alcoceba M, Valera A, Campo E, Lopez A. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3). DOI:10.1111/bjh.17858. PMID:34632572. IF:6,5 (Q1/3D). Document type: Article.
Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang JX, Wierzbowska A, Lowenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. BLOOD. 2022; 140(12). DOI:10.1182/blood.2022016867. PMID:35797463. IF:20,3 (Q1/1D). Document type: Article.
Dreyling M, Andre M, Gokbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Ribera JM, Zweegman S, Aurer I, Bodor C, Burkhardt B, Buske C, Caballero MD, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Gronbaek K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman J, Le S, Lenz G, Leppa S, Lopez A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trumper LH, Salles G. The EHA Research Roadmap: Malignant Lymphoid Diseases. 2022; 6(6):e726. DOI:10.1097/HS9.0000000000000726. PMID:35620592. IF:6,6 (Q1/2D). Document type: Article.
Encinas C, Hernandez JA, Oriol A, Rosinol L, Blanchard MJ, Bellon JM, Garcia R, de la Rubia J, de la Guia AL, Jimenez A, Jarque I, Inigo B, Dourdil V, de Arriba F, Perez CC, Gonzalez Y, Hernandez MT, Bargay J, Granell M, Rodriguez P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez MS, Sureda A, Sampol A, Ocio EM, Krsnik I, Garcia A, Garcia A, Soler JA, Martin J, Arguinano JM, Mateos MV, Blade J, San JF, Lahuerta JJ, Martinez J, GEM PETHEMA Espanol Mieloma GRPPR. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2022; 12(4):68. DOI:10.1038/s41408-022-00652-2. PMID:35440057. IF:12,8 (Q1/1D). Document type: Article.
Falgàs A, Garcia A, Núñez Y, Serna N, Sánchez L, Unzueta U, Voltà E, Aragó M, Álamo P, Alba L, Sierra J, Gallardo A, Villaverde A, Vázquez E, Mangues R, Casanova I. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4(+) lymphoma cells without toxicity in immunocompromised and immunocompetent mice. BIOMEDICINE & PHARMACOTHERAPY. 2022; 150:112940. DOI:10.1016/j.biopha.2022.112940. PMID:35421785. IF:7,5 (Q1/1D). Document type: Article.
Fernandez J, Cid J, Azqueta C, Valdivia E, Martorell L, Codinach M, Marsal J, Mussetti A, Esquirol A, Trabazo M, Benitez MI, Ferra C, Fox ML, Linares M, Alonso E, Garcia E, Garcia N, Medina L, Castillo N, Vall F, Garcia A, Pinacho A, Talarn C, Arroba JG, Coll R, Santos M, Valero O, Carreras E, Lozano M, Querol S. Post thawing viable CD34+Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(8). DOI:10.1038/s41409-022-01722-6. PMID:35614316. IF:4,8 (Q1/2D). Document type: Letter.
Fernandez J, Horton R, Cid J, Azqueta C, Garcia A, Valdivia E, Martorell L, Rubio N, Codinach M, Aran G, Marsal J, Mussetti A, Martino R, Diaz C, Ferra C, Valcarcel D, Linares M, Ancochea A, Garcia E, Garcia N, Medina L, Carreras E, Villa J, Lozano M, Gibson D, Querol S. Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. BONE MARROW TRANSPLANTATION. 2022; 57(10). DOI:10.1038/s41409-022-01750-2. PMID:35804055. IF:4,8 (Q1/2D). Document type: Article.
Garcia M, Hernandez JC, Alvarez A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, Garcia MC, Gomez MT, Ferrer F, Saavedra S, Cervantes F, Garcia R, Espanol Enfermedades Mieloprol GRP. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. 2022; 14(9):2331. DOI:10.3390/cancers14092331. PMID:35565461. IF:5,2 (Q2/3D). Document type: Article.
González C, Briones J, Sang H, García E. Marginal zone lymphoma under anti-TNF treatment in Crohn disease. Gastroenterologia y Hepatologia. 2022; 45(5). DOI:10.1016/j.gastrohep.2021.05.010. PMID:34118314. IF:1,9 (Q4/9D). Document type: Letter.
Guijarro F, Bataller A, Diaz M, Garrido A, Coll C, Vives S, Salamero O, Valcarcel D, Tormo M, Arnan M, Sampol A, Castano S, Martinez C, Suarez M, Fernandez F, Hernandez JC, Ribera JM, Rovira M, Brunet S, Sierra J, Esteve J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. BONE MARROW TRANSPLANTATION. 2022; 57(8). DOI:10.1038/s41409-022-01703-9. PMID:35643942. IF:4,8 (Q1/2D). Document type: Article.
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai WY, De La Cruz L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von GR, Lu HL, Yakovich A, Chen M, Ter JH, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. LEUKEMIA & LYMPHOMA. 2022; 63(4). DOI:10.1080/10428194.2021.2010057. PMID:34865586. IF:2,6 (Q3/7D). Document type: Article.
Hernandez JC, Pereira A, Zinger N, Gras L, Martino R, Paneesha S, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden JA, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan DP, Yakoub I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2022; 57(3). DOI:10.1038/s41409-021-01553-x. PMID:35066569. IF:4,8 (Q1/2D). Document type: Article.
Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Kako S, Tozatto K, Yanada M, Sanz G, Uchida N, Angelucci E, Kato S, Mohty M, Forcade E, Tanaka M, Sierra J, Ohta T, Saccardi R, Fukuda T, Ichinohe T, Kimura T, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. BONE MARROW TRANSPLANTATION. 2022; 57(1). DOI:10.1038/s41409-021-01479-4. PMID:34635798. IF:4,8 (Q1/2D). Document type: Article.
Lopez A, Canales MA, Dlouhy I, Mercadal S, Briones J, Garcia AM, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, Lopez A, Panizo C, Muntanola A, Montalban C, Conde E, Hernandez MT, Soler A, Marco J, Deben G, Marin J, Tomas JF. A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. LEUKEMIA & LYMPHOMA. 2022; 63(1). DOI:10.1080/10428194.2021.1971216. PMID:34459702. IF:2,6 (Q3/7D). Document type: Article.
Lopez S, Martinez A, Rodriguez A, Vinuela A, Brown AA, Martin L, Vilalta N, Arus M, Panousis NI, Buil A, Sabater M, Souto JC, Dermitzakis ET, Soria JM. Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk. THROMBOSIS AND HAEMOSTASIS. 2022; 122(06). DOI:10.1055/s-0041-1742169. PMID:35272364. IF:10,4 (Q1/1D). Document type: Article.
Martino R, Garcia I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(2). DOI:10.1038/s41409-021-01507-3. PMID:34711914. IF:4,8 (Q1/2D). Document type: Letter.
Meijide JB. Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas. Farmacia Hospitalaria. 2022; 46(3). DOI:10.7399/fh.13280. PMID:36183201. Document type: Editorial material.
Menghrajani K, Gomez A, Madero R, Zhang MJ, Bo K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, et al. [Martino R]. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3). DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7,5 (Q1/2D). Document type: Article.
Mercadal S, Alana M, Barcelo MI, Bruixola G, Lopez P, Bobillo S, Dlouhy I, Agud RC, Molina EG, Martinez P, Cacabelos P, Muntanola A, Garcia G, Sancho JM, Campos I, Lado T, Salar A, Caballero AC, Sole M, Velasco R. Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 197(6):18148. DOI:10.1111/bjh.18148. PMID:35307813. IF:6,5 (Q1/3D). Document type: Letter.
Merino M, Ivanova Y, Maravilla P, Barragan B, Sierra J, Penuelas A, Hidalgo A. Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment. EUROPEAN JOURNAL OF CANCER CARE. 2022; 31(6):e13706. DOI:10.1111/ecc.13706. PMID:36177961. IF:2,1 (Q2/5D). Document type: Article.
Mikulska M, Knelange N, Nicolini LA, Tridello G, Santarone S, Di P, de la Camara R, Cuellar C, Velardi A, Perruccio K, Ljungman P, Zaucha J, Piekarska A, Basak G, Karakulska E, Angelucci E, Ciceri F, Lupo MT, Fouillard L, Garcia I, Menconi M, Blau IW, Nassi L, Cesaro S, Styczynski J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1). DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28,2 (Q1/1D). Document type: Article.
Montero JCS, Gonzalez A, Aguilar LM, Cortes JM. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. Medicina Intensiva. 2022; 46(4). DOI:10.1016/j.medin.2020.06.014. PMID:32873409. IF:3 (Q3/7D). Document type: Article.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10,1 (Q1/2D). Document type: Article.
Moreno DF, Clapes V, Soler JA, Gonzalez Y, Gironella M, Motllo C, Granell M, Abella E, Garcia M, Garcia A, Cabezudo E, Blade J, Rosinol L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clinical Lymphoma Myeloma & Leukemia. 2022; 22(8). DOI:10.1016/j.clml.2022.04.014. PMID:35610120. IF:2,7 (Q3/7D). Document type: Article.
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, Levin M-D, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi Q, Steele A, Schuier N, Baeten K, Caces DB, Niemann C, Kater A. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22. DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:2,7 (Q3/7D). Document type: Article.
Nagler A, Labopin M, Cornelissen JJ, Forcade E, Chevallier P, Fegueux N, Sierra J, Desmier D, Labussiere H, Byrne JL, Loschi M, Blaise D, Baron F, Ruggeri A, Mohty M. Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION. 2022; 57(10). DOI:10.1038/s41409-022-01742-2. PMID:35773347. IF:4,8 (Q1/2D). Document type: Article.
Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol A, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3). DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7,5 (Q1/2D). Document type: Article.
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kroger N, Sierra J, Socie G, Cornelissen J, Poire X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub I. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. BONE MARROW TRANSPLANTATION. 2022; 57(6). DOI:10.1038/s41409-021-01555-9. PMID:35352038. IF:4,8 (Q1/2D). Document type: Article.
Orgueira AM, Perez MSG, Arias JD, Rosinol L, Oriol A, Teruel AI, Lopez JM, Palomera L, Granell M, Blanchard MJ, de la Rubia J, de la Guia AL, Rios R, Sureda A, Hernandez MT, Bengoechea E, Calasanz MJ, Gutierrez N, Martin ML, Blade J, Lahuerta JJ, San Miguel J, Mateos MV, PETHEMA GEM Cooperative GRP. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal. 2022; 12(4):76. DOI:10.1038/s41408-022-00647-z. PMID:35468898. IF:12,8 (Q1/1D). Document type: Article.
Pallares V, Unzueta U, Falgas A, Avino A, Nunez Y, Garcia A, Sanchez L, Serna N, Gallardo A, Alba L, Alamo P, Sierra J, Cedo L, Eritja R, Villaverde A, Vazquez E, Casanova I, Mangues R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. BIOMATERIALS. 2022; 280:121258. DOI:10.1016/j.biomaterials.2021.121258. PMID:34847435. IF:14 (Q1/1D). Document type: Article.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu QY, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. 2022; 139(23). DOI:10.1182/blood.2021011583. PMID:35081255. IF:20,3 (Q1/1D). Document type: Article.
Pinana JL, Garcia R, Martino R, Garcia M, Martin GA, Risco I, Tormo M, Martinez P, Marcos S, Calabuig M, Conesa V, Teruel A, Ruiz S, Solano C, Navarro D, Cedillo A, Sureda A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3). DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7,5 (Q1/2D). Document type: Letter.
Pinana JL, Lopez L, Martino R, Montoro J, Vazquez L, Perez A, Martin G, Facal A, Ferrer E, Pascual MJ, Sanz G, Gago B, Sanchez A, Villalon L, Conesa V, Olave MT, Lopez J, Marcos S, Garcia M, Garcia V, Hernandez JA, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer B, Guerreiro M, Ruiz M, Munoz JL, Navarro D, Cedillo A, Sureda A. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. AMERICAN JOURNAL OF HEMATOLOGY. 2022; 97(1). DOI:10.1002/ajh.26385. PMID:34695229. IF:12,8 (Q1/1D). Document type: Article.
Pinana JL, Lopez L, Martino R, Vazquez L, Perez A, Martin G, Gago B, Sanz G, Sanchez A, Villalon L, Conesa V, Olave MT, Corona M, Marcos S, Tormo M, Hernandez JA, Montoro J, Rodriguez A, Risco I, Rodriguez P, Hernandez JC, Garcia I, Ruiz M, Munoz JL, Solano C, Cedillo A, Sureda A, Navarro D, Spanish Hematopoietic Stem Cell TR. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology & Oncology. 2022; 15(1):54. DOI:10.1186/s13045-022-01275-7. PMID:35526045. IF:28,5 (Q1/1D). Document type: Article.
Pinana JL, Rodriguez P, Caballero D, Martino R, Lopez L, Terol MJ, Vazquez L, Calabuig M, Sanz G, Marin F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual MJ, Rodriguez A, Olave MT, Cascales A, Gago B, Hernandez JA, Villalon L, Corona M, Roldan A, Ribes J, Gonzalez C, Garcia R, Navarro D, Serrano AJ, Cedillo A, Soria E, Sureda A, Solano C, Spanish Hematopoietic Stem Cell TR. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. ANNALS OF HEMATOLOGY. 2022; 101(9). DOI:10.1007/s00277-022-04906-8. PMID:35780254. IF:3,5 (Q2/5D). Document type: Article.
Pinana JL, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez R, Garrido A, Sierra J, Ribera JM, Torrent A, Mateos MV, de la Rubia J, Tormo M, Diez M, Garcia V, Alvarez A, Sancho JM, MartinGarcia A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez I, Bonanad S, Lecumberri R, Ruiz I, Navarro D, Hernandez JA, Cedillo A, Garcia R, Bosch F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. LEUKEMIA & LYMPHOMA. 2022; 63(3). DOI:10.1080/10428194.2021.1992619. PMID:34668835. IF:2,6 (Q3/7D). Document type: Review.
Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault de Latour R, Esquirol A, Michel G, Chevallier P, Rubio MT, Cornelissen JJ, Michallet M, Volt F, Rivera MM, Scigliuolo GM, Cappelli B, Rocha V, Gluckman E. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Blood Advances. DOI:10.1182/bloodadvances.2022007941. PMID:36350759. IF:7,5 (Q1/2D). Document type: Article.
Ramos S, Puiggros A, Bea S, Bougeon S, Larrayoz MJ, Costa D, Parker H, Rigolin GM, Ortega M, Blanco ML, Collado R, Salgado R, Baumann T, Gimeno E, Moreno C, Bosch F, Calvo X, Calasanz MJ, Cuneo A, Strefford JC, Nguyen F, Oscier D, Haferlach C, Schoumans J, Espinet B. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. HAEMATOLOGICA. 2022; 107(3). DOI:10.3324/haematol.2020.274456. PMID:33691382. IF:10,1 (Q1/2D). Document type: Article.
Ramos S, Puiggros A, Kamaso J, Bea S, Bougeon S, Larrayoz MJ, Costa D, Parker H, Rigolin GM, Blanco ML, Collado R, Ancin I, Salgado R, Moro MA, Baumann T, Gimeno E, Moreno C, Salido M, Calvo X, Calasanz MJ, Cuneo A, Nguyen F, Oscier D, Haferlach C, Strefford JC, Schoumans J, Espinet B. TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. 2022; 14(15):3715. DOI:10.3390/cancers14153715. PMID:35954380. IF:5,2 (Q2/3D). Document type: Article.
Redondo S, Esquirol A, Novelli S, Caballero AC, Garrido A, Onate G, Lopez J, Moreno C, Saavedra SD, Granell M, Briones J, Sierra J, Martino R, Garcia I. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation And Cellular Therapy. 2022; 28(1). DOI:10.1016/j.jtct.2021.10.015. PMID:34757054. IF:3,2 (Q2/5D). Document type: Article.
Reinoso M, Caballero T, Herrera P, Patriarca F, Fanin R, Bruno B, Einsele H, Nahi H, Granell M, Lopez L, Reguera JL, Garcia I, Gahrton G, Perez JA, European N, European Soc Blood Marrow T, Spanish GRP. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation And Cellular Therapy. 2022; 28(5). DOI:10.1016/j.jtct.2022.01.026. PMID:35131486. IF:3,2 (Q2/5D). Document type: Article.
Ribera J, Granada I, Morgades M, Gonzalez T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, Gonzalez J, Tormo M, Garcia I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermudez A, Orfao A, Ribera JM. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3). DOI:10.1111/bjh.17844. PMID:34549416. IF:6,5 (Q1/3D). Document type: Article.
Ribera JM, Garcia O, Buendia B, Terol MJ, Vicent A, Vall F, Bergua J, Garcia I, Esteve J, Ribera J, Acuna E, Herrera P, Hernandez JM, Abrisqueta P, Gonzalez J, Rodriguez C, Bastos M, Genesca E, Caminos N, de Llano MPQ, Cladera A, Sancho JM. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. LEUKEMIA & LYMPHOMA. 2022; 63(8). DOI:10.1080/10428194.2022.2053531. PMID:35343365. IF:2,6 (Q3/7D). Document type: Letter.
Rucker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Dohner H, Thiede C, Dohner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. 2022; 36(1). DOI:10.1038/s41375-021-01323-0. PMID:34316017. IF:11,4 (Q1/1D). Document type: Article.
Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner CM, Zaja F, Robson S, MacGregor L, Tschopp RR, Nick S, Dreyling M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study. HAEMATOLOGICA. 2022; 107(2). DOI:10.3324/haematol.2020.274803. PMID:34134469. IF:10,1 (Q1/2D). Document type: Article.
Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringden O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation And Cellular Therapy. 2022; 28(10). DOI:10.1016/j.jtct.2022.07.013. PMID:35853610. IF:3,2 (Q2/5D). Document type: Article.
Santos MF, Almorox RB, Solan L, Lopez O, Gallardo A, Garcia S, Esquirol A, Ferra C, Martin A, Garcia A, Perez E, Colorado M, Cortes M, Cabrero M, Gayoso J, Yañez L, Pascual MJ, Heras IDL, Diez JL, Caballero MD, Kwon M, Corral LL. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC). Clinical Lymphoma Myeloma & Leukemia. 2022; 22. DOI:10.1016/S2152-2650(22)01659-7. PMID:36164212. IF:2,7 (Q3/7D). Document type: Article.
Serna N, Falgas A, Garcia A, Unzueta U, Nunez Y, Sanchez A, Martinez C, Mangues R, Vazquez E, Casanova I, Villaverde A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. 2022; 14(1):192. DOI:10.3390/pharmaceutics14010192. PMID:35057088. IF:5,4 (Q1/2D). Document type: Article.
Serna N, Pallares V, Unzueta U, Garcia A, Volta E, Sanchez A, Parlade E, Rueda A, Casanova I, Falgas A, Alba L, Sierra J, Villaverde A, Vazquez E, Mangues R. Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. JOURNAL OF CONTROLLED RELEASE. 2022; 343. DOI:10.1016/j.jconrel.2022.01.017. PMID:35051493. IF:10,8 (Q1/1D). Document type: Article.
Soria JM, Mojal S, Martinez A, Acosta FR, López S, Miqueleiz S, Rodriguez D, Quijada MA, Cardenas A, Vidal F, Remacha A, Antonijoan RM, Souto JC. A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2022.281068. PMID:35545920. IF:10,1 (Q1/2D). Document type: Article.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22). DOI:10.1182/blood.2021014488. PMID:35196370. IF:20,3 (Q1/1D). Document type: Article.
Waszczuk A, Penack O, Sbianchi G, Koster L, Blaise D, Remenyi P, Russell N, Ljungman P, Trneny M, Mayer J, Iacobelli S, Kobbe G, Scheid C, Apperley J, Touzeau C, Lenhoff S, Jantunen E, Anagnostopoulos A, Paris L, Browne P, Thieblemont C, Schaap N, Sierra J, Yakoub I, Garderet L, Styczynski J, Schoemans H, Moiseev I, Duarte RF, Peric Z, Montoto S, van A, Mikulska M, Aljurf M, Ruutu T, Kroger N, Morris C, Koenecke C, Schoenland S, Basak GW. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine. 2022; 11(12):3541. DOI:10.3390/jcm11123541. PMID:35743620. IF:3,9 (Q2/4D). Document type: Article.
Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada N, Marks DI, Al AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan MA, Lazarus HM, Ganguly S, Bredeson C, Perez M, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances. 2022; 6(1). DOI:10.1182/bloodadvances.2021004916. PMID:34547770. IF:7,5 (Q1/2D). Document type: Article.
Zozaya N, Villaseca J, Abdalla F, Calleja MA, Diez JL, Estevez J, Garcia R, Martinez J, Sierra J, Vera R, Hidalgo A. A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clinical & Translational Oncology. 2022; 24(6). DOI:10.1007/s12094-021-02757-9. PMID:34997475. IF:3,4 (Q3/6D). Document type: Review.

Publications 2021

Albiol N, Arguello M, Moreno C. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. CURRENT OPINION IN ONCOLOGY. 2021; 33(6). DOI:10.1097/CCO.0000000000000791. PMID:34474439. IF:3,915.
Albiol N, Moreno C. Autoimmune Cytopenia in CLL Prognosis and Management in the Era of Targeted Therapies. CANCER JOURNAL. 2021; 27(4). DOI:10.1097/PPO.0000000000000537. PMID:34398555. IF:2,074.
Alvarez C, Escriba L, Caballero AC, Escudero E, Ujaldon C, Montserrat R, Pujol P, Sierra J, Briones J. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Clinical & Translational Immunology. 2021; 10(4):e1268. DOI:10.1002/cti2.1268. PMID:33968404. IF:6,515.
Bento L, Gutierrez A, Novelli S, Montoro J, Pinana JL, Lopez L, Cabrero M, Martin A, Gutierrez G, Ortiz M, Bastos M, Dorado N, Perez A, Hernani R, Ferra C, Parody R, Garcia I, Herrera P, Rodriguez G, Rodriguez N, Martin C, Yanez L, Zanabili J, Varela MR, Lopez O, Heras I, Espanol I, Martinez C, Perez JA, Solano C, Sureda A, Sierra J, Sampol A, Caballero D. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. BONE MARROW TRANSPLANTATION. 2021; 56(8). DOI:10.1038/s41409-021-01264-3. PMID:33767400. IF:5,174.
Bueno F, Solano C, Vazquez L, Gimenez E, de la Camara R, Albert E, Rovira M, Espigado I, Calvo CM, Lopez J, Suarez M, Chinea A, Esquirol A, Perez A, Bermudez A, Saldana R, Heras I, Gonzalez AJ, Torrado T, Batlle M, Jimenez S, Vallejo C, Barba P, Cuesta MA, Duarte R, Pinana JL, Navarro D. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transplant Infectious Disease. 2021; 23(4):e13627. DOI:10.1111/tid.13627. PMID:33908148. IF:2,228.
Cid J, Monsalvo S, Castillo C, Pascual C, Moreno G, Lopez M, Andon C, Guerra L, Esquirol A, Sanchez I, Ortega S, Zalba S, Martinez C, Rovira M, Marin P, Lozano M. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH). TRANSFUSION AND APHERESIS SCIENCE. 2021; 60(2):103052. DOI:10.1016/j.transci.2021.103052. PMID:33483284. IF:2,596.
Dickinson M, Briones J, Herrera AF, Gonzalez E, Ghosh N, Cordoba R, Rutherford SC, Bournazou E, Labriola E, Franjkovic I, Chesne E, Brouwer J, Lechner K, Brennan B, Nuesch E, DeMario M, Ruttinger D, Kornacker M, Hutchings M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 2021; 5(22). DOI:10.1182/bloodadvances.2021004619. PMID:34581757. IF:7,637.
Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang YW, Paulson JN, Chang YM, Musick L, Abrisqueta P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematology. 2021; 8(12). PMID:34826412. IF:30,153.
Esquirol A, Pascual MJ, Kwon M, Perez A, Parody R, Ferra C, Cadenas IG, Herruzo B, Dorado N, Hernani R, Sanchez I, Torrent A, Sierra J, Martino R. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2021; 56(10). DOI:10.1038/s41409-021-01328-4. PMID:34059802. IF:5,174.
Falgas A, Pallares V, Unzueta U, Nunez Y, Sierra J, Gallardo A, Alba L, Mangues MA, Alamo P, Villaverde A, Vazquez E, Mangues R, Casanova I. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4(+) Diffuse Large B-Cell Lymphoma Cells. International Journal of Nanomedicine. 2021; 1D6OI:10.2147/IJN.S289733. PMID:33716502. IF:7,033.
Fernandez J, Azqueta C, Valdivia E, Martorell L, Medina L, Martinez N, Torrents S, Codinach M, Canals C, Elorza I, Parody R, Martino R, Trabazo M, de Heredia CD, Ferra C, Valcarcel D, Linares M, Ancochea A, Garcia E, Garcia N, Medina L, Castillo N, Carreras E, Villa J, Querol S. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?. BONE MARROW TRANSPLANTATION. 2021; 56(10). DOI:10.1038/s41409-021-01367-x. PMID:34127808. IF:5,174.
Genesca E, Morgades M, Gonzalez C, Fuster F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martinez D, Garcia I, Vives S, Ribera J, Gonzalez J, Diaz M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermudez A, Vall F, Martinez P, Amigo ML, Monsalvo S, Novo A, Cervera M, Garcia A, Ciudad J, Cervera J, et al. Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). LEUKEMIA RESEARCH. 2021; 109:106612. DOI:10.1016/j.leukres.2021.106612. PMID:34139642. IF:3,715.
González-Barca E, Capote FJ, Gómez-Codina J, Panizo C, Salar A, Sancho JM, López A, Briones J, Muñoz A, Encuentra M, Mercadal S, Domingo-Domenech E, de Sevilla AF; GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas). Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. Annals of Hematology. 2021;100(4):1023-1029. DOI:10.1007/s00277-020-04056-9. PMID: 32367180. IF:4,030.
Granell M, Senin A, Barata A, Cibeira MT, Gironella M, Lopez J, Motllo C, Garcia A, Ben R, Abella E, Soler A, Canet M, Marti JM, Martino R, Sierra J, de Larrea CF, Oriol A, Rosinol L. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. BONE MARROW TRANSPLANTATION. 2021; 56(12). DOI:10.1038/s41409-021-01429-0. PMID:34404917. IF:5,174.
Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M, Gill D, Gribben JG, Flinn IW, Wang ZY, Cheung LWK, Nguyen AN, Zhou C, Styles L, Demirkan F. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. ANNALS OF HEMATOLOGY. 2021; 100(7). DOI:10.1007/s00277-021-04536-6. PMID:34018029. IF:4,030.
Iacoboni G, Villacampa G, Martinez N, Bailen R, Corral LL, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Garcia AM, Kwon M, Reguera JL, Barba P. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Medicine. 2021; 10(10). DOI:10.1002/cam4.3881. PMID:33932100. IF:4,711.
Jimenez A, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen KR, Abdel H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez M, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, et al. [Martino R]. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. BONE MARROW TRANSPLANTATION. 2021; 56(12). DOI:10.1038/s41409-021-01450-3. PMID:34584240. IF:5,174.
Larson RA, Mandrekar SJ, Huebner LJ, Sanford B, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. LEUKEMIA. 2021; 35(9). DOI:10.1038/s41375-021-01179-4. PMID:33654204. IF:12,883.
Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Al Zahrani M, Apperley J, Berceanu A, Bofarull RM, Calbacho M, Ciceri F, Lopez L, Crippa C, Fox ML, Grassi A, Jimenez MJ, Demir SK, Kwon M, Llamas CV, Lorenzo JLL, Mielke S, Orchard K, Porras RP, Vallisa D, Xhaard A, Knelange NS, Cedillo A, Kroger N, Pinana JL, Styczynski J. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. LEUKEMIA. 2021; 35(10). DOI:10.1038/s41375-021-01302-5. PMID:34079042. IF:12,883.
Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Díaz de Heredia C, Fortuny-Guasch C, García-Cadenas I, García-Vidal C, González-Vicent M, Hernani R, Kwon M, Machado M, Martínez-Gómez X, Maldonado VO, Pla CP, Piñana JL, Pomar V, Reguera-Ortega JL, Salavert M, Soler-Palacín P, Vázquez-López L, Barba P, Ruiz-Camps I. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49(2):215-231. DOI:10.1007/s15010-020-01521-5. PMID: 32979154. IF:7,455.
Moreno C, Munoz C, Terol MJ, Hernandez JA, Villanueva M. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2021; 40(1):321. DOI:10.1186/s13046-021-02115-1. PMID:34654437. IF:12,658.
Oriol A, Ibarra G, Abella E, Motlló C, Cibeira MT, Garcia A, Escoda L, Granell M, Ben-Azaiz R, Cervera M, Cabezudo E, Fernandez C, Rosiñol L. Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma. Leukemia Lymphoma. 2021;62(1):125-135. DOI:10.1080/10428194.2020.1817439. PMID: 32933355. IF:2,996.
Pallares V, Nunez Y, Sanchez L, Falgas A, Serna N, Unzueta U, Gallardo A, Alba L, Alamo P, Sierra J, Villaverde A, Vazquez E, Casanova I, Mangues R. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. JOURNAL OF CONTROLLED RELEASE. 2021; 335. DOI:10.1016/j.jconrel.2021.05.014. PMID:34004204. IF:11,467.
Payan S, Perez LG, Sevilla A, Gil JS, Canales SN. Absolute Lymphocytes, Ferritin, C-Reactive Protein, and Lactate Dehydrogenase Predict Early Invasive Ventilation in Patients With COVID-19. LABORATORY MEDICINE. 2021; 52(2). DOI:10.1093/labmed/lmaa105. PMID:33336243. IF: 1,865.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, Garcia I, Moreno MJ, Martinez D, Torrent A, Martinez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, Gonzalez J, Rodriguez C, Bermudez A, Novo A, Soria B, Coll R, Amigo ML, Lopez A, Fernandez R, Serrano J, Mercadal S, Cladera A, Gimenez A, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. BLOOD. 2021; 137(14). DOI:10.1182/blood.2020007311. PMID:33150388. IF:25,476.
Ribera JM, Morgades M, Coll R, Barba P, Lopez JL, Montesinos P, Foncillas MA, Cabrero M, Gomez I, Morales MD, Varela MR, Herrera P, Garcia I, Calbacho M, Torrent A, Maluquer C, Calabuig M, Garcia A, Bautista G, Llorente L, Gil C, Artola MT, Gonzalez J, Fernandez A, Barez A, Gimenez T, Bergua J, Sanchez MJ, Mateos MC, Pinana JL. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Clinical Lymphoma Myeloma & Leukemia. 2021; 21(10). DOI:10.1016/j.clml.2021.06.024. PMID:34376375. IF:2,822.
Ribera JM, Morgades M, Genesca E, Chapchap EC, Montesinos P, Acuna E, Gil C, Garcia I, Barba P, Gonzalez J, de Llano MPQ, Torrent A, Ribera J, Granada I, Bernal T, Diaz M, Amigo ML, Coll R, Tormo M, Vall F, Gomez I, Sanchez MJ, Soria B, Cladera A, Artola MT, Garcia A, Gimenez A, Amador ML, Martinez P, Algarra JL, Vidal MJ, Alonso N, Maluquer C, et al. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. HEMATOLOGICAL ONCOLOGY. 2021; 39(4). DOI:10.1002/hon.2910. PMID:34405901. IF:4,850.
Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Piñana JL, Navarro D; Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH). Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplantation. 2021;56(6):1281-1290. DOI: 10.1038/s41409-020-01157-x. PMID: 33319853. IF:5,174.
Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Bautista G, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Piñana JL, Navarro D. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. AMERICAN JOURNAL OF TRANSPLANTATION. 2021;21(1):258-271. DOI:10.1111/ajt.16147. PMID: 32812351. IF:9,369.
Vachon H, Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Fortpied C, Flechtner HH, Maraldo MV, Hutchings M, Meijnders P, Aleman B, Lugtenburg P, Spina M, Andre M, Hertzberg M, Briones J, Bottomley A, EORTC Quality Life Lymphoma GRPGR. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. EUROPEAN JOURNAL OF HAEMATOLOGY. 2021; 106(5). DOI:10.1111/ejh.13601. PMID:33570765. IF:3,674.
Vicent MG, de Heredia CD, de Pablo JG, Molina B, Regueiro A, Martinez AP, Palomo P, Corral LL, Garcia E, Fernandez JM, Perez A, Jimenez MJ, Guerreiro M, Vallejo C, Gallardo AI, Lopez O, Benito A, Marsal J, Duarte M, Bento L, Badell I, Pedraza A, Ubieto AJ, Gonzalez P, Centurion IG, Costilla L, Belendez C, Esquirol A, Espigado I, Lavilla E, Diaz MA. Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH). EUROPEAN JOURNAL OF HAEMATOLOGY. 2021; 106(6). DOI:10.1111/ejh.13618. PMID:33713387. IF:3,674.

2017 Scientific Report – Oncology-Haematology and Transplantation

Introduction

Main lines of research

Study of the molecular and cellular pathophysiology of haematological cancers.
Study of the prognostic value of clinical and biological parameters in haematological malignancies.
Design of new modalities of chemotherapy, biotherapy and drug treatment targeting molecular mechanisms.
Design of new modalities of haematopoietic stem-cell transplantation and cell therapy.
Psychological intervention and quality of life in patients with haematological malignancies.

Challenges

Identify new prognostic parameters for risk and therapeutic stratification.
Evaluate targeted therapy in cell lines and animal models (with the Oncogenesis and Antitumour Drugs group).
Reduce toxicity and increase availability of allogeneic transplants.
Molecularly characterize acute myeloid leukaemia and determine the prognostic value of known genes and other genes of uncertain significance (with the Haematology Laboratory).
Model leukaemia and lymphoma in animals to better understand cell physiopathology and test new drugs (with the Oncogenesis and Antitumour Drugs group).
Molecularly characterize and determine the prognostic significance of cell physiopathology and immunotherapy for lymphoproliferative diseases and evaluate antitumour immunotherapy in animals and humans.

Team

Group coordination

BRIONES MEIJIDE, JAVIER FGS
jbriones@santpau.cat

Members

Scientific output

Publications 2022

(JIF 2022)

Albiol N, Barata A, Aso O, Gomez L, Triquell M, Roch N, Lazaro E, Esquirol A, Gonzalez I, Lopez J, Sierra J, Martino R, Garcia I. mRNA-1273 SARS-CoV-2 vaccine safety and COVID-19 risk perception in recently transplanted allogeneic hematopoietic stem cell transplant recipients. SUPPORTIVE CARE IN CANCER. 2022; 30(12). DOI:10.1007/s00520-022-07376-w. PMID:36169731. IF:3,1 (Q1/3D). Document type: Article.
Allan JN, Shanafelt T, Wiestner A, Moreno C, O’Brien SM, Li JL, Krigsfeld G, Dean JP, Ahn IE. Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(4). DOI:10.1111/bjh.17984. PMID:34865212. IF:6,5 (Q1/3D). Document type: Article.
Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, Wang SA, Bagg A, Barbui T, Branford S, Bueso CE, Cortes JE, Dal P, DiNardo CD, Dombret H, Duncavage EJ, Ebert BL, Estey EH, Facchetti F, Foucar K, Gangat N, Gianelli U, Godley LA, Gokbuget N, Gotlib J, Hellstrom E, Hobbs GS, Hoffman R, Jabbour EJ, Kiladjian JJ, Larson RA, Le MM, Loh MLC, et al. [Sierra J]. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. BLOOD. 2022; 140(11). DOI:10.1182/blood.2022015850. PMID:35767897. IF:20,3 (Q1/1D). Document type: Article.
Arguello M, Albiol N, Jara P, Sierra J, Mora A, Moreno C. CLL-477 Historical Trends in the Front-Line Treatment in Patients With Chronic Lymphocytic Leukemia: Experience from a European Center. Clinical Lymphoma Myeloma & Leukemia. 2022; 22. DOI:10.1016/S2152-2650(22)01349-0. PMID:36163896. IF:2,7 (Q3/7D). Document type: Article.
Arranz MJ, Salazar J, Bote V, Artigas A, Serra A, Trivino E, Roige J, Lombardia C, Cancino M, Hernandez M, Cendros M, Duran E, Maraver N, Hervas A. Pharmacogenetic Interventions Improve the Clinical Outcome of Treatment-Resistant Autistic Spectrum Disorder Sufferers. 2022; 14(5):999. DOI:10.3390/pharmaceutics14050999. PMID:35631585. IF:5,4 (Q1/2D). Document type: Article.
Baptista MJ, Tapia G, Munoz AM, Muncunill J, Garcia O, Montoto S, Gribben JG, Calaminici M, Martinez A, Veloza L, Martinez A, Aldamiz T, Menarguez J, Terol MJ, Ferrandez A, Alcoceba M, Briones J, Gonzalez E, Climent F, Muntanola A, Moraleda JM, Provencio M, Abrisqueta P, Abella E, Colomo L, Garcia C, Garcia M, Sancho JM, Ribera JM, Mate JL, Navarro JT. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. HISTOPATHOLOGY. 2022; 81(6). DOI:10.1111/his.14798. PMID:36109172. IF:6,4 (Q1/2D). Document type: Article.
Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, Hillmen P, Coutre SE, Dearden C, Grosicki S, McCarthy H, Li J-Y, Offner F, Moreno C, Zhou C, Hsu E, Szoke A, Kipps TJ, Ghia P. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11). DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7,5 (Q1/2D). Document type: Article.
Bataller A, Garrido A, Guijarro F, Onate G, Diaz M, Arnan M, Tormo M, Vives S, de Llano MPQ, Coll R, Gallardo D, Vall F, Escoda L, Garcia A, Salamero O, Sampol A, Merchan BM, Bargay J, Castano S, Esteban D, Oliver A, Rivero A, Mozas P, Lopez M, Pratcorona M, Zamora L, Costa D, Rozman M, Nomdedeu JF, Colomer D, Brunet S, Sierra J, Esteve J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances. 2022; 6(4). DOI:10.1182/bloodadvances.2021005585. PMID:34911079. IF:7,5 (Q1/2D). Document type: Article.
Bazarbachi A, Boumendil A, Finel H, Khvedelidze I, Romejko J, Tanase A, Akhtar S, Ben T, Ma’koseh M, Afanasyev B, Cheikh J, Briones J, Gulbas Z, Hamladji RM, Elverdi T, Blaise D, Martinez C, Alma E, Halaburda K, Sousa AB, Glass B, Robinson S, Montoto S, Sureda A. The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years. LEUKEMIA. 2022; 36(6). DOI:10.1038/s41375-022-01563-8. PMID:35414657. IF:11,4 (Q1/1D). Document type: Article.
Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, Munir T, Stevens DA, Dai S, Cheung LWK, Kwei K, Lal I, Hsu EM, Kipps TJ, Tedeschi A. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. LEUKEMIA & LYMPHOMA. 2022; 63(6). DOI:10.1080/10428194.2021.2020779. PMID:35014928. IF:2,6 (Q3/7D). Document type: Article.
Caballero AC, Escriba L, Alvarez C, Briones J. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology. 2022; 13:904497. DOI:10.3389/fimmu.2022.904497. PMID:35874685. IF:7,3 (Q1/3D). Document type: Review.
Corrochano M, Acosta R, Mojal S, Miqueleiz S, Rodriguez D, Quijada MA, Fraga E, Castillo M, Amaro K, Albiol N, Soria JM, Antonijoan RM, Souto JC. Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. JOURNAL OF THROMBOSIS AND THROMBOLYSIS. 2022; 53(1). DOI:10.1007/s11239-021-02507-2. PMID:34138399. IF:4 (Q2/4D). Document type: Article.
Diaz J, Rodriguez R, Coll R, Osca G, Pratcorona M, Gonzalez M, Garrido A, Angona A, Talarn C, Tormo M, Arnan M, Vives S, Salamero O, Tuset E, Lloveras N, Diez I, Zamora L, Bargay J, Sampol A, Cruz D, Vila J, Sitges M, Garcia A, Vall F, Esteve J, Sierra J, Gallardo D, Cooperativo Estudio Tratamient GRP. 5 ‘-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics. EUROPEAN JOURNAL OF HAEMATOLOGY. 2022; 109(6). DOI:10.1111/ejh.13862. PMID:36063368. IF:3,1 (Q3/6D). Document type: Article.
Dlouhy I, Karube K, Enjuanes A, Salaverria I, Nadeu F, Ramis JE, Valero JG, Rivas A, Magnano L, Martin D, Perez P, Clot G, Rovira J, Jares P, Balague O, Gine E, Mozas P, Briones J, Sancho JM, Salar A, Mercadal S, Alcoceba M, Valera A, Campo E, Lopez A. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3). DOI:10.1111/bjh.17858. PMID:34632572. IF:6,5 (Q1/3D). Document type: Article.
Dohner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA, Levine RL, Miyazaki Y, Niederwieser D, Ossenkoppele G, Rollig C, Sierra J, Stein EM, Tallman MS, Tien HF, Wang JX, Wierzbowska A, Lowenberg B. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. BLOOD. 2022; 140(12). DOI:10.1182/blood.2022016867. PMID:35797463. IF:20,3 (Q1/1D). Document type: Article.
Dreyling M, Andre M, Gokbuget N, Tilly H, Jerkeman M, Gribben J, Ferreri A, Morel P, Stilgenbauer S, Fox C, Ribera JM, Zweegman S, Aurer I, Bodor C, Burkhardt B, Buske C, Caballero MD, Campo E, Chapuy B, Davies A, de Leval L, Doorduijn J, Federico M, Gaulard P, Gay F, Ghia P, Gronbaek K, Goldschmidt H, Kersten MJ, Kiesewetter B, Landman J, Le S, Lenz G, Leppa S, Lopez A, Macintyre E, Mantega MVM, Moreau P, Moreno C, Nadel B, Okosun J, Owen R, Pospisilova S, Pott C, Robak T, Spina M, Stamatopoulos K, Stary J, Tarte K, Tedeschi A, Thieblemont C, Trappe RU, Trumper LH, Salles G. The EHA Research Roadmap: Malignant Lymphoid Diseases. 2022; 6(6):e726. DOI:10.1097/HS9.0000000000000726. PMID:35620592. IF:6,6 (Q1/2D). Document type: Article.
Encinas C, Hernandez JA, Oriol A, Rosinol L, Blanchard MJ, Bellon JM, Garcia R, de la Rubia J, de la Guia AL, Jimenez A, Jarque I, Inigo B, Dourdil V, de Arriba F, Perez CC, Gonzalez Y, Hernandez MT, Bargay J, Granell M, Rodriguez P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez MS, Sureda A, Sampol A, Ocio EM, Krsnik I, Garcia A, Garcia A, Soler JA, Martin J, Arguinano JM, Mateos MV, Blade J, San JF, Lahuerta JJ, Martinez J, GEM PETHEMA Espanol Mieloma GRPPR. A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal. 2022; 12(4):68. DOI:10.1038/s41408-022-00652-2. PMID:35440057. IF:12,8 (Q1/1D). Document type: Article.
Falgàs A, Garcia A, Núñez Y, Serna N, Sánchez L, Unzueta U, Voltà E, Aragó M, Álamo P, Alba L, Sierra J, Gallardo A, Villaverde A, Vázquez E, Mangues R, Casanova I. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4(+) lymphoma cells without toxicity in immunocompromised and immunocompetent mice. BIOMEDICINE & PHARMACOTHERAPY. 2022; 150:112940. DOI:10.1016/j.biopha.2022.112940. PMID:35421785. IF:7,5 (Q1/1D). Document type: Article.
Fernandez J, Cid J, Azqueta C, Valdivia E, Martorell L, Codinach M, Marsal J, Mussetti A, Esquirol A, Trabazo M, Benitez MI, Ferra C, Fox ML, Linares M, Alonso E, Garcia E, Garcia N, Medina L, Castillo N, Vall F, Garcia A, Pinacho A, Talarn C, Arroba JG, Coll R, Santos M, Valero O, Carreras E, Lozano M, Querol S. Post thawing viable CD34+Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(8). DOI:10.1038/s41409-022-01722-6. PMID:35614316. IF:4,8 (Q1/2D). Document type: Letter.
Fernandez J, Horton R, Cid J, Azqueta C, Garcia A, Valdivia E, Martorell L, Rubio N, Codinach M, Aran G, Marsal J, Mussetti A, Martino R, Diaz C, Ferra C, Valcarcel D, Linares M, Ancochea A, Garcia E, Garcia N, Medina L, Carreras E, Villa J, Lozano M, Gibson D, Querol S. Leukocytapheresis variables and transit time for allogeneic cryopreserved hpc: better safe than sorry. BONE MARROW TRANSPLANTATION. 2022; 57(10). DOI:10.1038/s41409-022-01750-2. PMID:35804055. IF:4,8 (Q1/2D). Document type: Article.
Garcia M, Hernandez JC, Alvarez A, Raya JM, Angona A, Estrada N, Fox L, Cuevas B, Garcia MC, Gomez MT, Ferrer F, Saavedra S, Cervantes F, Garcia R, Espanol Enfermedades Mieloprol GRP. Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis. 2022; 14(9):2331. DOI:10.3390/cancers14092331. PMID:35565461. IF:5,2 (Q2/3D). Document type: Article.
González C, Briones J, Sang H, García E. Marginal zone lymphoma under anti-TNF treatment in Crohn disease. Gastroenterologia y Hepatologia. 2022; 45(5). DOI:10.1016/j.gastrohep.2021.05.010. PMID:34118314. IF:1,9 (Q4/9D). Document type: Letter.
Guijarro F, Bataller A, Diaz M, Garrido A, Coll C, Vives S, Salamero O, Valcarcel D, Tormo M, Arnan M, Sampol A, Castano S, Martinez C, Suarez M, Fernandez F, Hernandez JC, Ribera JM, Rovira M, Brunet S, Sierra J, Esteve J. Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. BONE MARROW TRANSPLANTATION. 2022; 57(8). DOI:10.1038/s41409-022-01703-9. PMID:35643942. IF:4,8 (Q1/2D). Document type: Article.
Halwani AS, Panizo C, Isufi I, Herrera AF, Okada CY, Cull EH, Kis B, Chaves JM, Bartlett NL, Ai WY, De La Cruz L, Bryan LJ, Houot R, Linton K, Briones J, Chau I, von GR, Lu HL, Yakovich A, Chen M, Ter JH, Yurasov S, Hsu FJ, Flowers CR. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. LEUKEMIA & LYMPHOMA. 2022; 63(4). DOI:10.1080/10428194.2021.2010057. PMID:34865586. IF:2,6 (Q3/7D). Document type: Article.
Hernandez JC, Pereira A, Zinger N, Gras L, Martino R, Paneesha S, Finke J, Chinea A, Rambaldi A, Robin M, Saccardi R, Natale A, Snowden JA, Tsirigotis P, Vallejo C, Wulf G, Xicoy B, Russo D, Maertens J, Daguindau E, Lenhoff S, Hayden P, Czerw T, McLornan DP, Yakoub I. Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2022; 57(3). DOI:10.1038/s41409-021-01553-x. PMID:35066569. IF:4,8 (Q1/2D). Document type: Article.
Kanda J, Hayashi H, Ruggeri A, Kimura F, Volt F, Takahashi S, Kako S, Tozatto K, Yanada M, Sanz G, Uchida N, Angelucci E, Kato S, Mohty M, Forcade E, Tanaka M, Sierra J, Ohta T, Saccardi R, Fukuda T, Ichinohe T, Kimura T, Rocha V, Okamoto S, Nagler A, Atsuta Y, Gluckman E. The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. BONE MARROW TRANSPLANTATION. 2022; 57(1). DOI:10.1038/s41409-021-01479-4. PMID:34635798. IF:4,8 (Q1/2D). Document type: Article.
Lopez A, Canales MA, Dlouhy I, Mercadal S, Briones J, Garcia AM, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, Lopez A, Panizo C, Muntanola A, Montalban C, Conde E, Hernandez MT, Soler A, Marco J, Deben G, Marin J, Tomas JF. A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. LEUKEMIA & LYMPHOMA. 2022; 63(1). DOI:10.1080/10428194.2021.1971216. PMID:34459702. IF:2,6 (Q3/7D). Document type: Article.
Lopez S, Martinez A, Rodriguez A, Vinuela A, Brown AA, Martin L, Vilalta N, Arus M, Panousis NI, Buil A, Sabater M, Souto JC, Dermitzakis ET, Soria JM. Integrated GWAS and Gene Expression Suggest ORM1 as a Potential Regulator of Plasma Levels of Cell-Free DNA and Thrombosis Risk. THROMBOSIS AND HAEMOSTASIS. 2022; 122(06). DOI:10.1055/s-0041-1742169. PMID:35272364. IF:10,4 (Q1/1D). Document type: Article.
Martino R, Garcia I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. BONE MARROW TRANSPLANTATION. 2022; 57(2). DOI:10.1038/s41409-021-01507-3. PMID:34711914. IF:4,8 (Q1/2D). Document type: Letter.
Meijide JB. Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas. Farmacia Hospitalaria. 2022; 46(3). DOI:10.7399/fh.13280. PMID:36183201. Document type: Editorial material.
Menghrajani K, Gomez A, Madero R, Zhang MJ, Bo K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, et al. [Martino R]. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3). DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7,5 (Q1/2D). Document type: Article.
Mercadal S, Alana M, Barcelo MI, Bruixola G, Lopez P, Bobillo S, Dlouhy I, Agud RC, Molina EG, Martinez P, Cacabelos P, Muntanola A, Garcia G, Sancho JM, Campos I, Lado T, Salar A, Caballero AC, Sole M, Velasco R. Ocular involvement in patients with primary central-nervous-system lymphoma: Analysis of a multicentre study in Spain. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 197(6):18148. DOI:10.1111/bjh.18148. PMID:35307813. IF:6,5 (Q1/3D). Document type: Letter.
Merino M, Ivanova Y, Maravilla P, Barragan B, Sierra J, Penuelas A, Hidalgo A. Optimising the management of patients with multiple myeloma in Spain: A measurement of the social return on investment. EUROPEAN JOURNAL OF CANCER CARE. 2022; 31(6):e13706. DOI:10.1111/ecc.13706. PMID:36177961. IF:2,1 (Q2/5D). Document type: Article.
Mikulska M, Knelange N, Nicolini LA, Tridello G, Santarone S, Di P, de la Camara R, Cuellar C, Velardi A, Perruccio K, Ljungman P, Zaucha J, Piekarska A, Basak G, Karakulska E, Angelucci E, Ciceri F, Lupo MT, Fouillard L, Garcia I, Menconi M, Blau IW, Nassi L, Cesaro S, Styczynski J. Efficacy, safety and feasibility of treatment of chronic HCV infection with directly acting agents in hematopoietic stem cell transplant recipients – Study of infectious diseases working party of EBMT. JOURNAL OF INFECTION. 2022; 84(1). DOI:10.1016/j.jinf.2021.10.024. PMID:34757138. IF:28,2 (Q1/1D). Document type: Article.
Montero JCS, Gonzalez A, Aguilar LM, Cortes JM. Immune effector cell-associated neurotoxicity syndrome: A therapeutic approach in the critically ill. Medicina Intensiva. 2022; 46(4). DOI:10.1016/j.medin.2020.06.014. PMID:32873409. IF:3 (Q3/7D). Document type: Article.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Novak J, Strugov V, Gill D, Gribben JG, Kwei K, Dai S, Hsu E, Dean JP, Flinn IW. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10,1 (Q1/2D). Document type: Article.
Moreno DF, Clapes V, Soler JA, Gonzalez Y, Gironella M, Motllo C, Granell M, Abella E, Garcia M, Garcia A, Cabezudo E, Blade J, Rosinol L. Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas. Clinical Lymphoma Myeloma & Leukemia. 2022; 22(8). DOI:10.1016/j.clml.2022.04.014. PMID:35610120. IF:2,7 (Q3/7D). Document type: Article.
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, Levin M-D, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi Q, Steele A, Schuier N, Baeten K, Caces DB, Niemann C, Kater A. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22. DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:2,7 (Q3/7D). Document type: Article.
Nagler A, Labopin M, Cornelissen JJ, Forcade E, Chevallier P, Fegueux N, Sierra J, Desmier D, Labussiere H, Byrne JL, Loschi M, Blaise D, Baron F, Ruggeri A, Mohty M. Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). BONE MARROW TRANSPLANTATION. 2022; 57(10). DOI:10.1038/s41409-022-01742-2. PMID:35773347. IF:4,8 (Q1/2D). Document type: Article.
Onate G, Bataller A, Garrido A, Hoyos M, Arnan M, Vives S, Coll R, Tormo M, Sampol A, Escoda L, Salamero O, Garcia A, Bargay J, Aljarilla A, Nomdedeu JF, Esteve J, Sierra J, Pratcorona M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3). DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7,5 (Q1/2D). Document type: Article.
Onida F, Sbianchi G, Radujkovic A, Sockel K, Kroger N, Sierra J, Socie G, Cornelissen J, Poire X, Raida L, Bourhis JH, Finke J, Passweg J, Salmenniemi U, Schouten HC, Beguin Y, Martin S, Deconinck E, Ganser A, Zver S, Lioure B, Rohini R, Koster L, Hayden P, Iacobelli S, Robin M, Yakoub I. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. BONE MARROW TRANSPLANTATION. 2022; 57(6). DOI:10.1038/s41409-021-01555-9. PMID:35352038. IF:4,8 (Q1/2D). Document type: Article.
Orgueira AM, Perez MSG, Arias JD, Rosinol L, Oriol A, Teruel AI, Lopez JM, Palomera L, Granell M, Blanchard MJ, de la Rubia J, de la Guia AL, Rios R, Sureda A, Hernandez MT, Bengoechea E, Calasanz MJ, Gutierrez N, Martin ML, Blade J, Lahuerta JJ, San Miguel J, Mateos MV, PETHEMA GEM Cooperative GRP. Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal. 2022; 12(4):76. DOI:10.1038/s41408-022-00647-z. PMID:35468898. IF:12,8 (Q1/1D). Document type: Article.
Pallares V, Unzueta U, Falgas A, Avino A, Nunez Y, Garcia A, Sanchez L, Serna N, Gallardo A, Alba L, Alamo P, Sierra J, Cedo L, Eritja R, Villaverde A, Vazquez E, Casanova I, Mangues R. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model. BIOMATERIALS. 2022; 280:121258. DOI:10.1016/j.biomaterials.2021.121258. PMID:34847435. IF:14 (Q1/1D). Document type: Article.
Perl AE, Larson RA, Podoltsev NA, Strickland S, Wang ES, Atallah E, Schiller GJ, Martinelli G, Neubauer A, Sierra J, Montesinos P, Recher C, Yoon SS, Hosono N, Onozawa M, Chiba S, Kim HJ, Hasabou N, Lu QY, Tiu R, Levis MJ. Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. 2022; 139(23). DOI:10.1182/blood.2021011583. PMID:35081255. IF:20,3 (Q1/1D). Document type: Article.
Pinana JL, Garcia R, Martino R, Garcia M, Martin GA, Risco I, Tormo M, Martinez P, Marcos S, Calabuig M, Conesa V, Teruel A, Ruiz S, Solano C, Navarro D, Cedillo A, Sureda A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3). DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7,5 (Q1/2D). Document type: Letter.
Pinana JL, Lopez L, Martino R, Montoro J, Vazquez L, Perez A, Martin G, Facal A, Ferrer E, Pascual MJ, Sanz G, Gago B, Sanchez A, Villalon L, Conesa V, Olave MT, Lopez J, Marcos S, Garcia M, Garcia V, Hernandez JA, Saus A, Espigado I, Alonso C, Hernani R, Solano C, Ferrer B, Guerreiro M, Ruiz M, Munoz JL, Navarro D, Cedillo A, Sureda A. SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group. AMERICAN JOURNAL OF HEMATOLOGY. 2022; 97(1). DOI:10.1002/ajh.26385. PMID:34695229. IF:12,8 (Q1/1D). Document type: Article.
Pinana JL, Lopez L, Martino R, Vazquez L, Perez A, Martin G, Gago B, Sanz G, Sanchez A, Villalon L, Conesa V, Olave MT, Corona M, Marcos S, Tormo M, Hernandez JA, Montoro J, Rodriguez A, Risco I, Rodriguez P, Hernandez JC, Garcia I, Ruiz M, Munoz JL, Solano C, Cedillo A, Sureda A, Navarro D, Spanish Hematopoietic Stem Cell TR. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders. Journal of Hematology & Oncology. 2022; 15(1):54. DOI:10.1186/s13045-022-01275-7. PMID:35526045. IF:28,5 (Q1/1D). Document type: Article.
Pinana JL, Rodriguez P, Caballero D, Martino R, Lopez L, Terol MJ, Vazquez L, Calabuig M, Sanz G, Marin F, Alonso C, Montoro J, Ferrer E, Facal A, Pascual MJ, Rodriguez A, Olave MT, Cascales A, Gago B, Hernandez JA, Villalon L, Corona M, Roldan A, Ribes J, Gonzalez C, Garcia R, Navarro D, Serrano AJ, Cedillo A, Soria E, Sureda A, Solano C, Spanish Hematopoietic Stem Cell TR. Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients. ANNALS OF HEMATOLOGY. 2022; 101(9). DOI:10.1007/s00277-022-04906-8. PMID:35780254. IF:3,5 (Q2/5D). Document type: Article.
Pinana JL, Vazquez L, Martino R, de la Camara R, Sureda A, Rodriguez R, Garrido A, Sierra J, Ribera JM, Torrent A, Mateos MV, de la Rubia J, Tormo M, Diez M, Garcia V, Alvarez A, Sancho JM, MartinGarcia A, Yanez L, Simon J, Barba P, Abrisqueta P, Alvarez I, Bonanad S, Lecumberri R, Ruiz I, Navarro D, Hernandez JA, Cedillo A, Garcia R, Bosch F. Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients. LEUKEMIA & LYMPHOMA. 2022; 63(3). DOI:10.1080/10428194.2021.1992619. PMID:34668835. IF:2,6 (Q3/7D). Document type: Review.
Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault de Latour R, Esquirol A, Michel G, Chevallier P, Rubio MT, Cornelissen JJ, Michallet M, Volt F, Rivera MM, Scigliuolo GM, Cappelli B, Rocha V, Gluckman E. Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Blood Advances. DOI:10.1182/bloodadvances.2022007941. PMID:36350759. IF:7,5 (Q1/2D). Document type: Article.
Ramos S, Puiggros A, Bea S, Bougeon S, Larrayoz MJ, Costa D, Parker H, Rigolin GM, Ortega M, Blanco ML, Collado R, Salgado R, Baumann T, Gimeno E, Moreno C, Bosch F, Calvo X, Calasanz MJ, Cuneo A, Strefford JC, Nguyen F, Oscier D, Haferlach C, Schoumans J, Espinet B. Chromosome banding analysis and genomic microarrays are both useful but not equivalent methods for genomic complexity risk stratification in chronic lymphocytic leukemia patients. HAEMATOLOGICA. 2022; 107(3). DOI:10.3324/haematol.2020.274456. PMID:33691382. IF:10,1 (Q1/2D). Document type: Article.
Ramos S, Puiggros A, Kamaso J, Bea S, Bougeon S, Larrayoz MJ, Costa D, Parker H, Rigolin GM, Blanco ML, Collado R, Ancin I, Salgado R, Moro MA, Baumann T, Gimeno E, Moreno C, Salido M, Calvo X, Calasanz MJ, Cuneo A, Nguyen F, Oscier D, Haferlach C, Strefford JC, Schoumans J, Espinet B. TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype. 2022; 14(15):3715. DOI:10.3390/cancers14153715. PMID:35954380. IF:5,2 (Q2/3D). Document type: Article.
Redondo S, Esquirol A, Novelli S, Caballero AC, Garrido A, Onate G, Lopez J, Moreno C, Saavedra SD, Granell M, Briones J, Sierra J, Martino R, Garcia I. Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. Transplantation And Cellular Therapy. 2022; 28(1). DOI:10.1016/j.jtct.2021.10.015. PMID:34757054. IF:3,2 (Q2/5D). Document type: Article.
Reinoso M, Caballero T, Herrera P, Patriarca F, Fanin R, Bruno B, Einsele H, Nahi H, Granell M, Lopez L, Reguera JL, Garcia I, Gahrton G, Perez JA, European N, European Soc Blood Marrow T, Spanish GRP. Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. Transplantation And Cellular Therapy. 2022; 28(5). DOI:10.1016/j.jtct.2022.01.026. PMID:35131486. IF:3,2 (Q2/5D). Document type: Article.
Ribera J, Granada I, Morgades M, Gonzalez T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, Gonzalez J, Tormo M, Garcia I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermudez A, Orfao A, Ribera JM. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/ TCF3-PBX1 treated with measurable residual disease-oriented protocols. BRITISH JOURNAL OF HAEMATOLOGY. 2022; 196(3). DOI:10.1111/bjh.17844. PMID:34549416. IF:6,5 (Q1/3D). Document type: Article.
Ribera JM, Garcia O, Buendia B, Terol MJ, Vicent A, Vall F, Bergua J, Garcia I, Esteve J, Ribera J, Acuna E, Herrera P, Hernandez JM, Abrisqueta P, Gonzalez J, Rodriguez C, Bastos M, Genesca E, Caminos N, de Llano MPQ, Cladera A, Sancho JM. Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. LEUKEMIA & LYMPHOMA. 2022; 63(8). DOI:10.1080/10428194.2022.2053531. PMID:35343365. IF:2,6 (Q3/7D). Document type: Letter.
Rucker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I, Voso MT, Amadori S, Prior TW, Brandwein JM, Appelbaum FR, Medeiros BC, Tallman MS, Savoie L, Sierra J, Pallaud C, Sanz MA, Jansen JH, Niederwieser D, Fischer T, Ehninger G, Heuser M, Ganser A, Bullinger L, Larson RA, Bloomfield CD, Stone RM, Dohner H, Thiede C, Dohner K. Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. 2022; 36(1). DOI:10.1038/s41375-021-01323-0. PMID:34316017. IF:11,4 (Q1/1D). Document type: Article.
Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner CM, Zaja F, Robson S, MacGregor L, Tschopp RR, Nick S, Dreyling M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study. HAEMATOLOGICA. 2022; 107(2). DOI:10.3324/haematol.2020.274803. PMID:34134469. IF:10,1 (Q1/2D). Document type: Article.
Saliba RM, Alousi AM, Pidala J, Arora M, Spellman SR, Hemmer MT, Wang T, Abboud C, Ahmed S, Antin JH, Beitinjaneh A, Buchbinder D, Byrne M, Cahn JY, Choe H, Hanna R, Hematti P, Kamble RT, Kitko CL, Laughlin M, Lekakis L, MacMillan ML, Martino R, Mehta PA, Nishihori T, Patel SS, Perales MA, Rangarajan HG, Ringden O, Rosenthal J, Savani BN, Schultz KR, Seo S, Teshima T, van der Poel M, Verdonck LF, Weisdorf D, Wirk B, Yared JA, Schriber J, Champlin RE, Ciurea SO. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation And Cellular Therapy. 2022; 28(10). DOI:10.1016/j.jtct.2022.07.013. PMID:35853610. IF:3,2 (Q2/5D). Document type: Article.
Santos MF, Almorox RB, Solan L, Lopez O, Gallardo A, Garcia S, Esquirol A, Ferra C, Martin A, Garcia A, Perez E, Colorado M, Cortes M, Cabrero M, Gayoso J, Yañez L, Pascual MJ, Heras IDL, Diez JL, Caballero MD, Kwon M, Corral LL. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC). Clinical Lymphoma Myeloma & Leukemia. 2022; 22. DOI:10.1016/S2152-2650(22)01659-7. PMID:36164212. IF:2,7 (Q3/7D). Document type: Article.
Serna N, Falgas A, Garcia A, Unzueta U, Nunez Y, Sanchez A, Martinez C, Mangues R, Vazquez E, Casanova I, Villaverde A. Time-Prolonged Release of Tumor-Targeted Protein-MMAE Nanoconjugates from Implantable Hybrid Materials. 2022; 14(1):192. DOI:10.3390/pharmaceutics14010192. PMID:35057088. IF:5,4 (Q1/2D). Document type: Article.
Serna N, Pallares V, Unzueta U, Garcia A, Volta E, Sanchez A, Parlade E, Rueda A, Casanova I, Falgas A, Alba L, Sierra J, Villaverde A, Vazquez E, Mangues R. Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. JOURNAL OF CONTROLLED RELEASE. 2022; 343. DOI:10.1016/j.jconrel.2022.01.017. PMID:35051493. IF:10,8 (Q1/1D). Document type: Article.
Soria JM, Mojal S, Martinez A, Acosta FR, López S, Miqueleiz S, Rodriguez D, Quijada MA, Cardenas A, Vidal F, Remacha A, Antonijoan RM, Souto JC. A validated clinical-genetic score for assessing the risk of thrombosis in patients with COVID-19 receiving thromboprophylaxis. HAEMATOLOGICA. 2022; 107(9). DOI:10.3324/haematol.2022.281068. PMID:35545920. IF:10,1 (Q1/2D). Document type: Article.
Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, Barr PM, Tedeschi A, Trentin L, Bannerji R, Jackson S, Kuss BJ, Moreno C, Szafer E, Russell K, Zhou C, Ninomoto J, Dean JP, Wierda WG, Ghia P. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. BLOOD. 2022; 139(22). DOI:10.1182/blood.2021014488. PMID:35196370. IF:20,3 (Q1/1D). Document type: Article.
Waszczuk A, Penack O, Sbianchi G, Koster L, Blaise D, Remenyi P, Russell N, Ljungman P, Trneny M, Mayer J, Iacobelli S, Kobbe G, Scheid C, Apperley J, Touzeau C, Lenhoff S, Jantunen E, Anagnostopoulos A, Paris L, Browne P, Thieblemont C, Schaap N, Sierra J, Yakoub I, Garderet L, Styczynski J, Schoemans H, Moiseev I, Duarte RF, Peric Z, Montoto S, van A, Mikulska M, Aljurf M, Ruutu T, Kroger N, Morris C, Koenecke C, Schoenland S, Basak GW. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. Journal of Clinical Medicine. 2022; 11(12):3541. DOI:10.3390/jcm11123541. PMID:35743620. IF:3,9 (Q2/4D). Document type: Article.
Wieduwilt MJ, Metheny L, Zhang MJ, Wang HL, Estrada N, Marks DI, Al AS, Muffly L, Chao N, Rizzieri D, Gale RP, Gadalla SM, Cairo M, Mussetti A, Gore S, Bhatt VR, Patel SS, Michelis FV, Inamoto Y, Badawy SM, Copelan E, Palmisiano N, Kharfan MA, Lazarus HM, Ganguly S, Bredeson C, Perez M, Cassaday R, Savani BN, Ballen K, Martino R, Wirk B, Bacher U, Aljurf M, et al. Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. Blood Advances. 2022; 6(1). DOI:10.1182/bloodadvances.2021004916. PMID:34547770. IF:7,5 (Q1/2D). Document type: Article.
Zozaya N, Villaseca J, Abdalla F, Calleja MA, Diez JL, Estevez J, Garcia R, Martinez J, Sierra J, Vera R, Hidalgo A. A strategic reflection for the management and implementation of CAR-T therapy in Spain: an expert consensus paper. Clinical & Translational Oncology. 2022; 24(6). DOI:10.1007/s12094-021-02757-9. PMID:34997475. IF:3,4 (Q3/6D). Document type: Review.

Publications 2021

Albiol N, Arguello M, Moreno C. The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. CURRENT OPINION IN ONCOLOGY. 2021; 33(6). DOI:10.1097/CCO.0000000000000791. PMID:34474439. IF:3,915.
Albiol N, Moreno C. Autoimmune Cytopenia in CLL Prognosis and Management in the Era of Targeted Therapies. CANCER JOURNAL. 2021; 27(4). DOI:10.1097/PPO.0000000000000537. PMID:34398555. IF:2,074.
Alvarez C, Escriba L, Caballero AC, Escudero E, Ujaldon C, Montserrat R, Pujol P, Sierra J, Briones J. Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. Clinical & Translational Immunology. 2021; 10(4):e1268. DOI:10.1002/cti2.1268. PMID:33968404. IF:6,515.
Bento L, Gutierrez A, Novelli S, Montoro J, Pinana JL, Lopez L, Cabrero M, Martin A, Gutierrez G, Ortiz M, Bastos M, Dorado N, Perez A, Hernani R, Ferra C, Parody R, Garcia I, Herrera P, Rodriguez G, Rodriguez N, Martin C, Yanez L, Zanabili J, Varela MR, Lopez O, Heras I, Espanol I, Martinez C, Perez JA, Solano C, Sureda A, Sierra J, Sampol A, Caballero D. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study. BONE MARROW TRANSPLANTATION. 2021; 56(8). DOI:10.1038/s41409-021-01264-3. PMID:33767400. IF:5,174.
Bueno F, Solano C, Vazquez L, Gimenez E, de la Camara R, Albert E, Rovira M, Espigado I, Calvo CM, Lopez J, Suarez M, Chinea A, Esquirol A, Perez A, Bermudez A, Saldana R, Heras I, Gonzalez AJ, Torrado T, Batlle M, Jimenez S, Vallejo C, Barba P, Cuesta MA, Duarte R, Pinana JL, Navarro D. Assessment of the association between cytomegalovirus DNAemia and subsequent acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation: A multicenter study from the Spanish hematopoietic transplantation and cell therapy group. Transplant Infectious Disease. 2021; 23(4):e13627. DOI:10.1111/tid.13627. PMID:33908148. IF:2,228.
Cid J, Monsalvo S, Castillo C, Pascual C, Moreno G, Lopez M, Andon C, Guerra L, Esquirol A, Sanchez I, Ortega S, Zalba S, Martinez C, Rovira M, Marin P, Lozano M. Addition of plerixafor to G-CSF in poor mobilizing healthy related donors overcame mobilization failure: An observational case series on behalf of the Grupo Espanol de Trasplante Hematopoyetico (GETH). TRANSFUSION AND APHERESIS SCIENCE. 2021; 60(2):103052. DOI:10.1016/j.transci.2021.103052. PMID:33483284. IF:2,596.
Dickinson M, Briones J, Herrera AF, Gonzalez E, Ghosh N, Cordoba R, Rutherford SC, Bournazou E, Labriola E, Franjkovic I, Chesne E, Brouwer J, Lechner K, Brennan B, Nuesch E, DeMario M, Ruttinger D, Kornacker M, Hutchings M. Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. Blood Advances. 2021; 5(22). DOI:10.1182/bloodadvances.2021004619. PMID:34581757. IF:7,637.
Diefenbach C, Kahl BS, McMillan A, Briones J, Banerjee L, Cordoba R, Miall F, Burke JM, Hirata J, Jiang YW, Paulson JN, Chang YM, Musick L, Abrisqueta P. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Lancet Haematology. 2021; 8(12). PMID:34826412. IF:30,153.
Esquirol A, Pascual MJ, Kwon M, Perez A, Parody R, Ferra C, Cadenas IG, Herruzo B, Dorado N, Hernani R, Sanchez I, Torrent A, Sierra J, Martino R. Severe infections and infection-related mortality in a large series of haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2021; 56(10). DOI:10.1038/s41409-021-01328-4. PMID:34059802. IF:5,174.
Falgas A, Pallares V, Unzueta U, Nunez Y, Sierra J, Gallardo A, Alba L, Mangues MA, Alamo P, Villaverde A, Vazquez E, Mangues R, Casanova I. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4(+) Diffuse Large B-Cell Lymphoma Cells. International Journal of Nanomedicine. 2021; 1D6OI:10.2147/IJN.S289733. PMID:33716502. IF:7,033.
Fernandez J, Azqueta C, Valdivia E, Martorell L, Medina L, Martinez N, Torrents S, Codinach M, Canals C, Elorza I, Parody R, Martino R, Trabazo M, de Heredia CD, Ferra C, Valcarcel D, Linares M, Ancochea A, Garcia E, Garcia N, Medina L, Castillo N, Carreras E, Villa J, Querol S. Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations during the COVID-19 pandemic?. BONE MARROW TRANSPLANTATION. 2021; 56(10). DOI:10.1038/s41409-021-01367-x. PMID:34127808. IF:5,174.
Genesca E, Morgades M, Gonzalez C, Fuster F, Haferlach C, Meggendorfer M, Montesinos P, Barba P, Gil C, Coll R, Moreno MJ, Martinez D, Garcia I, Vives S, Ribera J, Gonzalez J, Diaz M, Mercadal S, Artola MT, Cladera A, Tormo M, Bermudez A, Vall F, Martinez P, Amigo ML, Monsalvo S, Novo A, Cervera M, Garcia A, Ciudad J, Cervera J, et al. Adverse prognostic impact of complex karyotype (>= 3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL). LEUKEMIA RESEARCH. 2021; 109:106612. DOI:10.1016/j.leukres.2021.106612. PMID:34139642. IF:3,715.
González-Barca E, Capote FJ, Gómez-Codina J, Panizo C, Salar A, Sancho JM, López A, Briones J, Muñoz A, Encuentra M, Mercadal S, Domingo-Domenech E, de Sevilla AF; GELTAMO (Spanish Lymphoma Group) and GOTEL (Group of Oncology for Therapy and Study of Lymphomas). Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. Annals of Hematology. 2021;100(4):1023-1029. DOI:10.1007/s00277-020-04056-9. PMID: 32367180. IF:4,030.
Granell M, Senin A, Barata A, Cibeira MT, Gironella M, Lopez J, Motllo C, Garcia A, Ben R, Abella E, Soler A, Canet M, Marti JM, Martino R, Sierra J, de Larrea CF, Oriol A, Rosinol L. Predictors of return to work after autologous stem cell transplantation in patients with multiple myeloma. BONE MARROW TRANSPLANTATION. 2021; 56(12). DOI:10.1038/s41409-021-01429-0. PMID:34404917. IF:5,174.
Greil R, Tedeschi A, Moreno C, Anz B, Larratt L, Simkovic M, Gill D, Gribben JG, Flinn IW, Wang ZY, Cheung LWK, Nguyen AN, Zhou C, Styles L, Demirkan F. Pretreatment with ibrutinib reduces cytokine secretion and limits the risk of obinutuzumab-induced infusion-related reactions in patients with CLL: analysis from the iLLUMINATE study. ANNALS OF HEMATOLOGY. 2021; 100(7). DOI:10.1007/s00277-021-04536-6. PMID:34018029. IF:4,030.
Iacoboni G, Villacampa G, Martinez N, Bailen R, Corral LL, Sanchez JM, Guerreiro M, Caballero AC, Mussetti A, Sancho JM, Hernani R, Abrisqueta P, Solano C, Sureda A, Briones J, Garcia AM, Kwon M, Reguera JL, Barba P. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Medicine. 2021; 10(10). DOI:10.1002/cam4.3881. PMID:33932100. IF:4,711.
Jimenez A, De Lima M, Komanduri KV, Wang TP, Zhang MJ, Chen KR, Abdel H, Abid MB, Aljurf M, Alkhateeb H, Assal A, Bacher U, Baron F, Battiwalla M, Beitinjaneh A, Bejanyan N, Bhatt VR, Byrne M, Cahn JY, Cairo M, Castillo P, Copelan E, DeFilipp Z, Perez M, Elsawy M, Gale RP, George B, Grunwald MR, Hildebrandt GC, Hogan WJ, Kanakry CG, et al. [Martino R]. An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. BONE MARROW TRANSPLANTATION. 2021; 56(12). DOI:10.1038/s41409-021-01450-3. PMID:34584240. IF:5,174.
Larson RA, Mandrekar SJ, Huebner LJ, Sanford B, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Voso MT, Klisovic RB, Galinsky I, Wei AH, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, et al. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. LEUKEMIA. 2021; 35(9). DOI:10.1038/s41375-021-01179-4. PMID:33654204. IF:12,883.
Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Al Zahrani M, Apperley J, Berceanu A, Bofarull RM, Calbacho M, Ciceri F, Lopez L, Crippa C, Fox ML, Grassi A, Jimenez MJ, Demir SK, Kwon M, Llamas CV, Lorenzo JLL, Mielke S, Orchard K, Porras RP, Vallisa D, Xhaard A, Knelange NS, Cedillo A, Kroger N, Pinana JL, Styczynski J. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. LEUKEMIA. 2021; 35(10). DOI:10.1038/s41375-021-01302-5. PMID:34079042. IF:12,883.
Los-Arcos I, Iacoboni G, Aguilar-Guisado M, Alsina-Manrique L, Díaz de Heredia C, Fortuny-Guasch C, García-Cadenas I, García-Vidal C, González-Vicent M, Hernani R, Kwon M, Machado M, Martínez-Gómez X, Maldonado VO, Pla CP, Piñana JL, Pomar V, Reguera-Ortega JL, Salavert M, Soler-Palacín P, Vázquez-López L, Barba P, Ruiz-Camps I. Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper. Infection. 2021;49(2):215-231. DOI:10.1007/s15010-020-01521-5. PMID: 32979154. IF:7,455.
Moreno C, Munoz C, Terol MJ, Hernandez JA, Villanueva M. Restoration of the immune function as a complementary strategy to treat Chronic Lymphocytic Leukemia effectively. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. 2021; 40(1):321. DOI:10.1186/s13046-021-02115-1. PMID:34654437. IF:12,658.
Oriol A, Ibarra G, Abella E, Motlló C, Cibeira MT, Garcia A, Escoda L, Granell M, Ben-Azaiz R, Cervera M, Cabezudo E, Fernandez C, Rosiñol L. Impact of response to treatment in health-related quality of life patient-reported outcomes in elderly patients with relapsed multiple myeloma. Leukemia Lymphoma. 2021;62(1):125-135. DOI:10.1080/10428194.2020.1817439. PMID: 32933355. IF:2,996.
Pallares V, Nunez Y, Sanchez L, Falgas A, Serna N, Unzueta U, Gallardo A, Alba L, Alamo P, Sierra J, Villaverde A, Vazquez E, Casanova I, Mangues R. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4. JOURNAL OF CONTROLLED RELEASE. 2021; 335. DOI:10.1016/j.jconrel.2021.05.014. PMID:34004204. IF:11,467.
Payan S, Perez LG, Sevilla A, Gil JS, Canales SN. Absolute Lymphocytes, Ferritin, C-Reactive Protein, and Lactate Dehydrogenase Predict Early Invasive Ventilation in Patients With COVID-19. LABORATORY MEDICINE. 2021; 52(2). DOI:10.1093/labmed/lmaa105. PMID:33336243. IF: 1,865.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genesca E, Barba P, Ribera J, Garcia I, Moreno MJ, Martinez D, Torrent A, Martinez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, Gonzalez J, Rodriguez C, Bermudez A, Novo A, Soria B, Coll R, Amigo ML, Lopez A, Fernandez R, Serrano J, Mercadal S, Cladera A, Gimenez A, et al. Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia. BLOOD. 2021; 137(14). DOI:10.1182/blood.2020007311. PMID:33150388. IF:25,476.
Ribera JM, Morgades M, Coll R, Barba P, Lopez JL, Montesinos P, Foncillas MA, Cabrero M, Gomez I, Morales MD, Varela MR, Herrera P, Garcia I, Calbacho M, Torrent A, Maluquer C, Calabuig M, Garcia A, Bautista G, Llorente L, Gil C, Artola MT, Gonzalez J, Fernandez A, Barez A, Gimenez T, Bergua J, Sanchez MJ, Mateos MC, Pinana JL. Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Clinical Lymphoma Myeloma & Leukemia. 2021; 21(10). DOI:10.1016/j.clml.2021.06.024. PMID:34376375. IF:2,822.
Ribera JM, Morgades M, Genesca E, Chapchap EC, Montesinos P, Acuna E, Gil C, Garcia I, Barba P, Gonzalez J, de Llano MPQ, Torrent A, Ribera J, Granada I, Bernal T, Diaz M, Amigo ML, Coll R, Tormo M, Vall F, Gomez I, Sanchez MJ, Soria B, Cladera A, Artola MT, Garcia A, Gimenez A, Amador ML, Martinez P, Algarra JL, Vidal MJ, Alonso N, Maluquer C, et al. Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials. HEMATOLOGICAL ONCOLOGY. 2021; 39(4). DOI:10.1002/hon.2910. PMID:34405901. IF:4,850.
Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Piñana JL, Navarro D; Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH). Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment. Bone Marrow Transplantation. 2021;56(6):1281-1290. DOI: 10.1038/s41409-020-01157-x. PMID: 33319853. IF:5,174.
Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, Chinea A, Esquirol A, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Bautista G, Batlle M, Jiménez S, Vallejo C, Barba P, Cuesta MÁ, Piñana JL, Navarro D. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: Analysis from the Spanish Hematopoietic Transplantation and Cell Therapy Group. AMERICAN JOURNAL OF TRANSPLANTATION. 2021;21(1):258-271. DOI:10.1111/ajt.16147. PMID: 32812351. IF:9,369.
Vachon H, Mierzynska J, Taye M, Pe M, Coens C, Martinelli F, Fortpied C, Flechtner HH, Maraldo MV, Hutchings M, Meijnders P, Aleman B, Lugtenburg P, Spina M, Andre M, Hertzberg M, Briones J, Bottomley A, EORTC Quality Life Lymphoma GRPGR. Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. EUROPEAN JOURNAL OF HAEMATOLOGY. 2021; 106(5). DOI:10.1111/ejh.13601. PMID:33570765. IF:3,674.
Vicent MG, de Heredia CD, de Pablo JG, Molina B, Regueiro A, Martinez AP, Palomo P, Corral LL, Garcia E, Fernandez JM, Perez A, Jimenez MJ, Guerreiro M, Vallejo C, Gallardo AI, Lopez O, Benito A, Marsal J, Duarte M, Bento L, Badell I, Pedraza A, Ubieto AJ, Gonzalez P, Centurion IG, Costilla L, Belendez C, Esquirol A, Espigado I, Lavilla E, Diaz MA. Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH). EUROPEAN JOURNAL OF HAEMATOLOGY. 2021; 106(6). DOI:10.1111/ejh.13618. PMID:33713387. IF:3,674.

ONCOHEMATOLOGIC DISEASES

Oncology/Haematology and Transplantation

Main lines of research

Challenges

Group coordination

Members

Publications 2022

Publications 2021

Main lines of research

Challenges

Group coordination

Members

Publications 2022

Publications 2021

Institut de Recerca de l’Hospital de la Santa Creu i Sant Pau